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Overstrain tendonitis are common pathologies in the sport horses. Therapeutic approaches to tendon healing do not always result in a satisfactory anatomical and functional repair, and healed tendon is often characterized by functional impairment and high risk of reinjury. Recently, mesenchymal stem cells (MSCs) and platelet rich plasma (PRP) have been proposed as novel therapeutic treatments to improve the tendon repair process. MSCs are multipotent, easy to culture and being originated from adult donors do not pose ethical issues. To date, autologous MSCs have been investigated mainly in the treatment of large bone defects, cardiovascular diseases, osteogenesis imperfecta and orthopaedic injuries both in human and veterinary medicine. The clinical applications in which autologous MSCs can be used are limited because patient-specific tissue collection and cell expansion require time. For clinical applications in which MSCs should be used right away, it would be more practical to use cells collected from a donor, expanded in vitro and banked to be readily available when needed. However, there are concerns over the safety and the efficacy of allogeneic MSCs. The safety and efficacy of a therapy based on the use of allogeneic adipose tissue-derived mesenchymal stem cells (ASCs) associated to platelet rich plasma (PRP) were evaluated in 19 horses affected by acute or subacute overstrain superficial digital flexor tendonitis (SDFT). The application of allogeneic ASCs neither raised clinical sign of acute or chronic adverse tissue reactions, nor the formation of abnormal tissue in the long term. After a follow-up of 24 months, 89.5% horses returned to their previous level of competition, while the reinjury rate was 10.5%, comparable to those recently reported for SDFT treated with autologous bone marrow derived MSCs. This study suggests that the association between allogeneic ASCs and PRP can be considered a safe and effective strategy for the treatment of SDF tendonitis in the horse.
Overstrain-induced tendon injuries are a common musculoskeletal disease affecting sport horses (1) . After an initial episode characterized by inflammation and lameness, overstrain tendonitis can evolve into a degeneration of the tendon matrix, leading to a loss of functionality of variable duration. Although the tissue is spontaneously repaired by scar tissue formation, lower mechanical strength, reduced elasticity and increased stiffness are common complications resulting in high risk of re-injury of the tendon (1-7). A variety of medical and surgical treatments associated with prolonged box-rest and carefully planned rehabilitation programs, have been proposed to improve tendon healing (1, 8) . Nevertheless, none of these therapeutic strategies is considered fully effective for a long-lasting functional recovery of the injured tendon (1, 5, (8) (9) (10) .
Recently, regenerative cell therapy based on the implantation of mesenchymal stem cells (MSCs), alone or in association with biological scaffolds, has turned out to be a promising therapeutic tool for musculoskeletal diseases in horses (5, (11) (12) (13) (14) (15) (16) . In fact, in the last few years, the application of MSCs in the treatment of tendon diseases in the horse has become almost-routine for many practitioners. Notably, despite the different approaches proposed in term of cell source, cell manipulation and/ or in-vitro expansion before implantation, most of the data reported by the literature have been focussed on the implantation of autologous bone marrow or adipose tissue-derived MSCs (5, 7, 11, (14) (15) (16) (17) (18) . Platelet rich plasma (PRP) represents a further tool that has been recently introduced in the therapy of tendon lesions both in human and domestic animals (7, 15) . The rationale behind the use of this treatment is that it allows the delivery to the damaged tissue of several growth promoting factors stored in circulating platelets, starting from an autologous blood sample processed with a relatively simple and fast procedure (15) .
The present report describes the long term outcome (24 months) of 19 clinical cases of horses affected by acute or sub-acute superficial digital-flexor tendonitis (SDFT) treated with allogeneic adipose tissue-derived mesenchymal stem cells (ASCs), in association with autologous platelet rich plasma (PRP). Results were evaluated by clinical examination, ultrasonographic imaging and performance results.
METHODS

Animals and clinical cases
Nineteen horses of different breeds and actrvines, affected by superficial digital flexor (SDF) tendonitis, aged between 3 to 18 years, were enrolled in the study (Table I) . Tendonitis were acute (less than 10 days old) in 12 horses or sub-acute (less than 20 days old) in 7 animals. The sites of the lesions were classified according to the Reef method [19] .
Stem cell isolation from adipose tissue
Cell isolation from adipose tissue and in vitro expansion was performed as previously described by Donofrio et al. (20) with minor modifications. Adipose tissue (approximately 15-20 grams) was collected from intra-abdominal fat deposit of6 adult horses at the abattoir immediately after slaughtering. Tissue was minced into small pieces under sterile conditions and washed several times with phosphate buffer saline solution (PBS) containing penicillin (1,000 IV/ml) and streptomycin (100 mg/ml) (Sigma-Aldrich Corp., ST. Louis, MO, USA). The tissue was then digested with 7.5 mg/ml type I collagenase (Sigma-Aldrich Corp., ST. Louis, MO, USA) in Dulbecco's modified Eagle's low glucose medium (DMEM) (Lonza, Inc. Rockland, ME, USA) under mild shaking for I hour at 37°C. After digestion, the remaining tissue fragments were removed, and cells suspension was filtered through a 50 urn nylon mesh and centrifuged at 250 g for 10 minutes. The supernatant was removed and the cell pellet resuspended in DMEM containing 10% v/v fetal bovine serum (FBS) (Lonza, Inc. Rockland, ME, USA), 1,000 IV/ml penicillin and 100 mg/ml streptomycin. Finally, cells were seeded in 25 ern-tissue culture flasks at the concentration of 5.0 xl 0 4 cells/em', and incubated at 37°C in 5% C02. After 48 hours non adherent cells were removed replacing the culture medium. Medium was renewed every 72 h thereafter. After the first passage (days 7-10), subsequent subcultures were performed when cells reached about 80% confluence. A maximum of four serial passages was performed.
Platelet Rich Plasma (PRP) preparation
PRPwas obtained from autologous whole venous blood collected with citrate-phosphate-dextrose. Fresh blood samples were aliquoted in 50 ml tubes and centrifuged at 150g for 30 minutes at 4°C. The erythrocyte fraction was discarded, while the plasma, enriched with platelets, was further centrifuged at 800g for 15 minutes. The platelet pellet was collected and platelets were then counted (CELL-DYN 3500R haematology analyser, Abbott) and diluted at a final concentration of 1.0xl 0 9 platelets/ml.
Adipose tissue-derived mesenchymal stem cells (ASCs) preparation for implantation
Forty-eight to twenty-four hours before implantation, cells were thawed and expanded in culture medium. Just before their implantation, ASCs (passages 3-4) were mildly trypsinized, centrifuged and counted. Cell viability was assessed by trypan blue exclusion assay. ASCs were diluted in autologous PRP to a volume proportional to the lesion's size (2-6 ml). Final cell concentration was 2.0xl0 6 cells/ml ofPRP. ASCs were stored at 4°C and used within 3 hours after preparation.
ASCs implantation and short term follow-up
Before cell implantation, lesion extension was assessed by clinical and ultrasound examination. Only lesions extending more than 15% of the cross-sectional area of the tendon were included in the clinical trial. Each lesion underwent a single injection of 2-6 ml of cell suspension (2.0 xl 0 6 cells/ml) in accordance to the lesion size, under ultrasonographic guidance. The horse was sedated with detomidine, 0.2 mg/horse (Detogesic; Fort Dodge Animal Health S.p.A., Bologna, Italy) by intravenous route. The area corresponding to SDFT lesion was shaved and disinfected, after which locoregional anaesthesia was performed with lidocaine 2% (Fort Dodge Animal Health S.p.A., Bologna, Italy). ASCs suspension was implanted in the core lesion using a 22-gauge needle. Sterile bandages were finally applied. The engrafted horses underwent ultrasound examination using instruments (Sonoace Pico,Milan, Italy or Esaote MyLab 40, Genova, Italy) equipped with a 7,5/10 MHz linear-shape probe, at 4, 8, 12, 16, 24 weeks after AMSCs implantation.
Short term follow up: animal welfare was strictly controlled in the first weeks after cells administration. Particular attention was given to detect any possible clinical sign of local immunological reaction, i.e. temperature raising, tissue swelling and lameness.
Rehabilitation
After the treatment, the horses were maintained on box rest for the first 7 days. The planned exercise programme applied thereafter is reported in Table 2 .
Statistical analysis
Fisher's exact test was used to evaluate differences in reinjury rate in animals treated with allogeneic ASCs compared to animals treated with different protocols using bone marrow derived MSCs (15, 16) or medical treatments alone (1). Statistical analysis was performed with WinPepi 10.2; P value <0.01 was considered significant.
RESULTS
Clinical outcome:
Clinical evaluation was carried out both on short term (i.e., weeks 0 to 4 after cell therapy), to highlight possible acute side effects of cell implantation, and long term (24 months), to evaluate the ability of the horses to return to their previous activity.
Allogeneic ASCs implantation did not induce any detrimental effect on the short term. ASCs did not hasten any acute, clinically valuable tendon reaction, and no signs oflameness, local swelling, heat or pain on palpation were reported after cell administration. No adverse reactions were observed in any treated animal by clinical examination during the rehabilitation period. Furthermore, ultrasonographic examination of the tendons did not give evidence of abnormal tissue within or around the implantation site in the long term. The ultrasound images showed a greater echogenicity of the tendon structures starting from 60-90 days after treatment, as expected for a regular evolution of the healing process ( Figure 1 ). After 6 months, no sign of lesion could be detected in injured tendon and fibers showed a correct alignment and a wellorganized longitudinal pattern. 
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With regard to the functional recovery of the horses, the fol1owing results were observed 24 months after treatment ( Table 3 , Allogeneic ASCs) : 17 out of 19 horses (89%) resumed their previous activity, while 2 out of 19 horses (11%) reinjured and did not return to their work.
DISCUSSION
In the present work we evaluated the safety and efficacy of the application of allogeneic ASCs in the therapy of superficial digital-flexor (SDF) tendon lesions in sport horses, when associated to platelet rich plasma (PRP) as a biological scaffold. SDF over-strain injuries are a common event in the sport horse (I , 7, 8) . Although the therapeutic approaches employed over the years have been aimed to accomplish the functional recovery of the tendon and to prevent the risk of tendon re-injury, they have been only partially successful. It is a common opinion that a reliable, definitive treatment for tendinopathy in the horse has yet to be achieved (5, 14, 16) .
In recent years, MSCs have been applied in the therapy of experimentally induced tendonitis (17, 21) as well as in the clinical treatment of over-strain induced tendon injuries in the horse with substantially positive outcomes (14) (15) (16) (22) (23) (24) (25) . Different strategies have been proposed, based mainly on the application of autologous bone marrow-derived MSCs (BSCs) or, alternatively, adipose tissue-derived MSCs (ASCs) . Both types of cells have been applied as nucleated cell fraction isolated from the tissue, without any further culture step, or after in-vitro expansion . Furthermore, their use has been in some case associated with support biological scaffolds , like platelet rich plasma (15) .
Interestingly, it has been reported that both BSCs and ASCs exhibit immunomodulatory properties and regulate immune cells proliferation , differentiation and phenotype in different animal species, although the molecular mechanisms underlying these effects are not clearly understood (26) (27) (28) . Even though no definitive invitro data are available, preliminary findings support the hypothesis that immunomodulatory and anti-inflammatory effects apply also to equine MSCs . In particular, Guest et al. reported that injection of allogeneic BSCs in experimental induced SDF tendonitis did not induce undesirable cell mediated immune response or external signs of inflammation (21, 29) . Furthermore, Carrade et al. recently reported that equine MSCs derived from bone marrow, adipose tissue, umbilical cord tissue and umbilical cord blood have immunomodulatory profiles similar to rodent and human MSCs (30) . These findings suggest the employment of allogeneic cells in the clinical practice. Autologous MSCs are certainly non-immunogenic and reduce the risks of transmission of infectious agents, but their application requires a delay in the therapy of twothree weeks needed for patient-specific cell expansion in vitro. Furthermore , the availability and the biological activity of cells isolated from older animal could be unsatisfactory (7, 31) . In contrast, allogeneic MSCs can be prepared, characterized and banked in advance (5, 7, 32) and hence provide a readily available source of "offthe-shelf' stem cells to be used at the proper time after the lesion occurrence (i.e. after the initial inflammation response, but before the development of a not organized scar tissue), without the need of time-demanding in vitro expansion (5) . To our knowledge, the clinical application of allogeneic MSCs derived from adipose tissue (ASCs) in the therapy of equine tendonitis has not been reported in the literature yet.
Nineteen horses affected by acute or sub-acute SDF tendonitis were followed for two years after allogeneic cell therapy administration. Allogeneic ASCs did not raise any acute or chronic clinical adverse reaction in the short or long term. Tissue swelling, temperature raising and lameness at walk were not reported in any animal following allogeneic cells implantation, nor was the formation ofabnormal tissue reported by ultrasonography or palpation after the 24 months follow-up. Furthermore , the functional recovery of the animals treated with allogeneic ASCs and PRP permitted the return to their previous level ofactivity to 89.5% of the horses, while the reinjuryrate observed was 10.5%. Different parameters can influence the prognosis of a therapeutic approach to SDF tendonitis. The treatment itself, but also the accompanying rehabilitation programme , the horse attitude, the type of work and/or racing and other uncontrolled factors, commonly detected in field conditions, play an important role in the functional recovery of the injured animals (5, 8, 16) . The horses enrolled in this study were of different breeds and working attitudes ( Table 1) . Despite these variable parameters, most of the clinical cases reported have shown the ability of the animals to return to their activity after the cell therapy and a strict adherence to a rehabilitation schedule and exercise programme.
Although the results of this work strongly suggest that allogeneic therapy is as safe as autologous MSCs therapy, they cannot prove directly the ability of ASCs therapy to improve tendon healing in comparison to more conventional therapies, nor the actual role of the cells in tissue healing. We are aware that the study has some limitations. No control group was included in this clinical cases report. In fact, a control population for clinical cases is quite difficult to obtain for equine industry (5, 7, 15, 16) , neither an animal treated as clinical case can be subjected to histological examination.
Although this could be considered a strong limitation, the aim of the work was not to perform a clinical trial, but rather to collect preliminary data on the safety and efficacy of the use allogeneic MSCs in the therapy of horse tendonitis.
Statistical analysis (Table III) , where the tendon lesion was treated with a medical approach alone. We are aware that the comparison of our results with these previously published works could be considered not strictly accurate, since the different attitudes of the animals can influence the evaluation of the clinical outcome. Nevertheless, the fact that no animal showed clinical signs of reaction to allogeneic cells therapy and that the ratio of animals returned to their athletic activity was comparable to those observed for animals treated with autologous MSC, can be considered a strong indication that allogeneic ASCs can be applied in the therapy of equine SDF lesions.
The proof of efficacy of the therapeutic role of ASCs, at the cellular and molecular level, can only come from experimental studies, although induced model tendonitis may have different characteristics from clinical tendon injuries. Recently, several experimental approaches have demonstrated that MSC (17, (21) (22) (23) and foetal embryonic like stem cells (32) can improve healing in experimental tendonitis models in the horse, although the exact role played by the engrafted cells has not been elucidated yet. It must be underlined that the therapeutic effect of mesenchymal stem cells could be related not only to their capacity to differentiate into mature, functional cells, but also to their immuno-modulatory properties, together with their abilityto stimulate functionalrecovery ofcells resident in the injured tissues, throughout the secretion of bioactive soluble factors (cytokines, growth factors) (33, 34) .
A further limit of the study could be the consideration that the association between allogeneic ASCs and PRP does not allow to separate the contribution to the healing process of the cell component from that of the biological scaffold. A role in tissue regeneration has been proposed for PRP through the local delivery of growth factors and other bioactive molecules (35) that could contribute to tendon healing stimulating replication and differentiation of the population of tissue-resident cells. The application of platelet derivatives in the treatment of tendon lesion have been already described both in equine and in human species (15, 35) . As discussed by Torricelli et al. (15) their combination with MSCs could improve the healing capacity of the tissue because of the cross-talk between MSCs, resident stem cells and bioactive molecules contributed by both PRP and MSCs. Furthermore, when associated to MSC treatment, the platelet gel derived from the clotting of the PRP could contribute a threedimensional scaffold, allowing a more homogeneous cell distribution inside the tendon lesion.
Deciphering the relative contribution of ASCs and PRP to tendon healing was beyond the scope of this work, and would have requested randomised control groups and a large number of animals. Nevertheless, the results have shown that the application of allogeneic ASCs in combination with PRP in the therapy of SDF tendonitis, was safe and resulted in promising clinical outcomes, confirming what already described for different treatment strategies based on the use of autologous MSCs. Further controlled in-vivo studies with higher number of animals and with the collection of histological, biochemical and biomechanical data will be required to demonstrate definitivelythat allogeneicASCs are a valuable therapeutic approach for tendon repair in the horse.
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